1- Musso R, Santagostino E, Faradji A, et al, for the KOGENATE®
Bayer European PMS Study Group.
Safety and efficacy of sucroseformulated full-length recombinant factor VIII: Experience in the standard clinical setting.
Thromb Haemost 2008; 99: 52–58
2-...
More
1- Musso R, Santagostino E, Faradji A, et al, for the KOGENATE®
Bayer European PMS Study Group.
Safety and efficacy of sucroseformulated full-length recombinant factor VIII: Experience in the standard clinical setting.
Thromb Haemost 2008; 99: 52–58
2- Kreuz W, Gill JC, Rothschild C, et al, and the International Kogenate-FS Study Group.
Full-length sucrose formulated recombinant F VIII
for treatment of previously untreated or minimally treated young children with severe hemophilia A.
Thromb Haemost 2005; 93: 457–467
3- Data on File
More than 8 billion units infused over
20 years, with zero confirmed cases of
pathogen transmission.
1,3
Low 15% incidence of inhibitor forma
in PUPs* & MTPs.
** 2
Excellent clinical response to bleeding
episodes with 1 or 2 infusions.
1,2
Improving treatment Safety
tion
More than 8 billion units infused over
20 years, with zero confirmed cases of
pathogen transmission.
1,3
Low 15% incidence of inhibitor forma
in PUPs* & MTPs.
** 2
Excellent clinical resp
Less
